Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Insights from antibody-drug conjugate research at SABCS 2024

Melissa Calopiz • 12 Dec 2024
SABCS 2024
Breast Cancer

Melissa Calopiz, University of Michigan, Ann Arbor, MI, shares her unique perspective on attending the 2024 San Antonio Breast Cancer Symposium (SABCS). Coming from a background in chemical engineering, she reflects on the exposure to patient-focused research and outcomes of antibody-drug conjugates (ADCs) and the valuable insights gained from other healthcare professionals at the event. This interview took place at the 2024 SABCS congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Melissa Calopiz

Reducing toxicity in future ADC design and combination therapy strategies
1:14
Reducing toxicity in future ADC design and combination therapy strategies
Melissa Calopiz • 12 Dec 2024
Optimizing antibody-drug conjugates with computational modelling
3:09
Optimizing antibody-drug conjugates with computational modelling
Melissa Calopiz • 12 Dec 2024

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals